BTAX Stock Overview
Biostax Corp. operates as a biopharmaceutical company that acquires and develops immune restoration pharmaceutical and medical technology products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Biostax Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.047 |
| 52 Week High | US$0.90 |
| 52 Week Low | US$0.045 |
| Beta | 0.0047 |
| 1 Month Change | -18.48% |
| 3 Month Change | -21.46% |
| 1 Year Change | -92.13% |
| 3 Year Change | -99.71% |
| 5 Year Change | -99.24% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| BTAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 0.4% | 1.0% |
| 1Y | -92.1% | 0.9% | 21.9% |
Return vs Industry: BTAX underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: BTAX underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| BTAX volatility | |
|---|---|
| BTAX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BTAX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine BTAX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Noreen Griffin | www.biostaxcorp.com |
Biostax Corp. operates as a biopharmaceutical company that acquires and develops immune restoration pharmaceutical and medical technology products. The company was formerly known as Immune Therapeutics, Inc. and changed its name to Biostax Corp. in October 2023. Biostax Corp. is based in Winter Park, Florida.
Biostax Corp. Fundamentals Summary
| BTAX fundamental statistics | |
|---|---|
| Market cap | US$3.95m |
| Earnings (TTM) | -US$1.65m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.4x
P/E RatioIs BTAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BTAX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$1.65m |
| Earnings | -US$1.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.02 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -31.0% |
How did BTAX perform over the long term?
See historical performance and comparison